Phase 1 / Phase 2: testing MK-3120 for Advanced Solid Tumors
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery.
Official registry: https://clinicaltrials.gov/study/NCT06818643 · Merck Sharp & Dohme LLC · enrollment listed as 270
What this phase means
Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are MK-3120. The registry lists allocation as randomized. Researchers are looking for new ways to treat people with certain advanced solid tumors.
They plan to enroll about 270 people at 49 sites. Taking part typically means an infusion or injection of a biologic plus check-ins.
Official title (unrewritten)
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors
Interventions: MK-3120
Primary outcome (registry wording): Number of Participants Who Experience an Adverse Event (AE)
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments
- If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART)
- If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
- If hepatitis C virus (HCV) infected, must have undetectable HCV viral load
Who the registry excludes
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
- Has uncontrolled significant cardiovascular disease or cerebrovascular disease
- Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
- Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
- Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 2 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Public study contact (from the registry)
Toll Free Number
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
49 listed- The University of Alabama at Birmingham ( Site 1005) — Birmingham, Alabama (recruiting)
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003) — Miami, Florida (recruiting)
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009) — Hackensack, New Jersey (recruiting)
- NEXT Oncology ( Site 1010) — Austin, Texas (recruiting)
- NEXT Oncology ( Site 1011) — Houston, Texas (recruiting)
- NEXT Oncology ( Site 1012) — Irving, Texas (recruiting)
- Virginia Commonwealth University ( Site 1008) — Richmond, Virginia (recruiting)
+ 42 sites outside the US on the same record
FAQ about this NCT record
Is NCT06818643 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT06818643?
Phase 1 / Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT06818643?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary